-
At close, the Nifty Pharma index was lower by 2.14 percent and 5.2 percent for the week, with most constituents in the red.
-
Malladi Drugs raised Rs 250 crore from healthcare and pharma focused private equity fund InvAscent. The PE fund holds around 22-23% stake in the company
-
For Moneycontrol Pro Panorama September 16 edition: Indian markets could be overestimating US Fed rate cut impact, equity tag for REITs a step towards global best practices, transformation of digital revolution and the road ahead, India’s growing influence in global diplomacy, and more
-
NPPA directs firms to issue revised price lists instead of recalling stock; compliance to be ensured at retailer level
-
Rates have been pruned for drugs used in chronic diseases as also medical devices and hospital chains
-
Labour-intensive exports to the US are expected to take the hardest hit as these sectors will face a rate of more than 50 percent given that Trump’s reciprocal tariffs are over and above the most favoured nation (MFN) duties in place.
-
India's duties on chemicals and pharmaceuticals are mostly in the range of 0-10 percent, with many pharmaceuticals at zero tariffs.
-
Sun Pharma’s top line growth is steady. Innovative medicines to act as growth tonic, as the US generics business remains soft. The stock valuation is justified.
-
Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors
-
The company has a CDMO pipeline of 90+ human health projects, wherein 15 products are commercialised, targeting APIs and intermediates
-
Reduced contribution of Revlimid is likely to get offset by new products
-
Cipla is expected to post muted profit growth for Q1FY26 despite steady revenue momentum, with US sales remaining flat and margin pressure weighing on the bottom line.
-
Brokerages expect steady revenue growth for Dr Reddy’s in Q1FY26, but caution that US price erosion and product mix could weigh on margins and bottomline.
-
Net Sales are expected to increase by 5.2 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 13,628.1 crore, according to ICICI Securities.
-
Net Sales are expected to decrease by 34.3 percent Y-o-Y (up 13.2 percent Q-o-Q) to Rs 552.4 crore, according to ICICI Securities.
-
Net Sales are expected to decrease by 9.8 percent Y-o-Y (up 16.1 percent Q-o-Q) to Rs 3,984.5 crore, according to ICICI Securities.
-
Net Sales are expected to increase by 1.8 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs 6,848.5 crore, according to ICICI Securities.
-
The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon.
-
If the drug succeeds, Glenmark could be staring at a royalty stream larger than its current EBITDA.
-
Many drugs with large market potential are expected to lose exclusivity in the next couple of years
-
In FY25 alone, the cash pile increased by over Rs 10,200 crore, underscoring a decisive shift in the capital allocation priorities of India’s drugmakers
-
Hyderabad-based Mapmygenome’s acquisition of Canada’s Microbiome Insights marks a critical moment in healthcare. It provides a platform to marry modern science with the wisdom and insight of Ayurveda. That, in turn, will allow India to lead a transformation in global healthcare
-
The fundamentals of the company should be judged based on the specialty pipeline and a strong footing in the domestic market
-
Pharma stocks appear to be recalibrating, while in their current phase, they are reflecting 'consolidation'. Meanwhile, analysts suggest the sector’s earnings visibility remains clouded.
-
Traction in private label business has infused positive momentum into MedPlus’s stock
